Example: Heart Attack

Clinical Trials on Mantle Cell Lymphoma

Total 1027 results

NCT03816683

Recruiting

A Disease Registry of Patients With Mantle Cell Lymphoma

Conditions: Mantle Cell Lymphoma
NCT01472562

Active, not recruiting

Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma

Conditions: Mantle Cell Lymphoma
NCT02840539

Recruiting

Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma

Conditions: Mantle Cell Lymphoma
NCT04718883

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Conditions: Mantle Cell Lymphoma
NCT03323151

Recruiting

A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

Conditions: Mantle-Cell Lymphoma
NCT03016988

Unknown status

The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma

Conditions: Mantle Cell Lymphoma
NCT01439750

Unknown status

Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)

Conditions: Mantle Cell Lymphoma
NCT04566887

Not yet recruiting

Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma

Conditions: Mantle Cell Lymphoma
NCT04061850

Completed

Ibrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Conditions: Mantle Cell Lymphoma
NCT04189757

Recruiting

Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma

Conditions: Mantle Cell Lymphoma
NCT00581854

Completed

Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma

Conditions: Mantle Cell Lymphoma
NCT04127916

Recruiting

Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL)

Conditions: Mantle Cell Lymphoma
NCT03836768

Active, not recruiting

BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma

Conditions: Mantle Cell Lymphoma
NCT04626791

Not yet recruiting

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Conditions: Mantle Cell Lymphoma
NCT04402138

Recruiting

Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma

Conditions: Mantle Cell Lymphoma
NCT04692155

Not yet recruiting

Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)

Conditions: Mantle Cell Lymphoma
NCT00581776

Completed

Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma

Conditions: Mantle Cell Lymphoma
NCT03616782

Recruiting

Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)

Conditions: Mantle Cell Lymphoma
NCT02735876

Withdrawn

A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Conditions: Mantle Cell Lymphoma
NCT03834688

Recruiting

Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age

Conditions: Mantle Cell Lymphoma
NCT03617484

Withdrawn

Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma

Conditions: Mantle Cell Lymphoma
NCT00843050

Terminated

A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma

Conditions: Mantle Cell Lymphoma
NCT03494179

Active, not recruiting

A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)

Conditions: Mantle Cell Lymphoma
NCT03623373

Active, not recruiting

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

Conditions: Mantle Cell Lymphoma
NCT03282396

Recruiting

Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma

Conditions: Mantle Cell Lymphoma